Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Kneat will release its financial results for the quarter ended December 31, 2025 on February 25, 2026 and host a conference call on February 26, 2026.
-
Beghou Names Meredith Ressi President and Chief Growth Officer to optimize for client experience and success.
-
SHANGHAI, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Headquartered in Shanghai, Arctic Vision (Cayman) Limited (“Arctic Vision”), a global ophthalmic company, announced that it has entered into an agreement...
-
Beghou's 2026 Biopharma Commercialization Research Report distills key insights, challenges, and operational realities for 2026 and beyond.
-
Soficitinib demonstrated a favorable safety profile and encouraging efficacy in treating patients with moderate-to-severe AD.
-
The global Vaccine Contract Manufacturing market is projected to grow at a CAGR of 10.9% by 2036 and reach US$11,065.6 million by 2036.
-
ANN ARBOR, Mich., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Peptinovo Biopharma, an Ann Arbor–based biotechnology company pioneering targeted cancer therapies through its first-of-its-kind proprietary PALM™...
-
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced...
-
NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation...
-
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...